CV Sciences, Inc.

Equities

CVSI

US1266541028

Pharmaceuticals

Delayed OTC Markets 02:33:02 2024-04-25 pm EDT 5-day change 1st Jan Change
0.0385 USD -2.92% Intraday chart for CV Sciences, Inc. +4.62% +8.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : CV Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024
CV Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews CI
CV Sciences, Inc. acquired Cultured Foods Sp. z.o.o for $0.535 million. CI
Transcript : CV Sciences, Inc., Q3 2023 Earnings Call, Nov 14, 2023
CV Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
CV Sciences, Inc. Launches Reserve Sleep Gummies CI
CV Sciences, Inc. Seeks Acquisitions CI
Transcript : CV Sciences, Inc., Q2 2023 Earnings Call, Aug 14, 2023
CV Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
CV Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
CV Sciences Seeks M&A Opportunities CI
Transcript : CV Sciences, Inc., Q1 2023 Earnings Call, May 15, 2023
Earnings Flash (CVSI) CV SCIENCES Posts Q1 EPS $0.04 MT
CV Sciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Transcript : CV Sciences, Inc., Q4 2022 Earnings Call, Mar 29, 2023
CV Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
CV Sciences, Inc. Receives Formal Notice of Patent Issuance from Japan Patent Office for Formulations Containing Cannabidiol and Nicotine for Treating Smokeless Tobacco Addiction CI
CV Sciences, Inc. Launches New Line of THC-Free Gummies and Softgels CI
CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection Softgels CI
Transcript : CV Sciences, Inc., Q3 2022 Earnings Call, Nov 14, 2022
Earnings Flash (CVSI) CV SCIENCES Posts Q3 Loss $-0.01 MT
CV Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
CV Sciences, Inc. Appoints William McCorkle as Director CI
Sector Update: Financial MT
Chart CV Sciences, Inc.
More charts
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). It also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based therapeutics. It develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under brands, such as +PlusCBD and Cultured Foods in the healthcare market sector, including nutraceutical, beauty care, specialty foods, and pet products. Its +PlusCBD branded products are sold at select retail locations throughout the United States. The Company's Cultured Foods brand provides a variety of 100% plant-based food products and caters to individuals seeking vegan, gluten-free, or flexitarian options for a culinary experience.
More about the company
  1. Stock Market
  2. Equities
  3. CVSI Stock
  4. News CV Sciences, Inc.
  5. Insider Trends: CV Sciences Insider Extends 90-Day Selling Trend